A. Wierzbicki

发表

The relationship between gonadotrophins, gonadal hormones and bone mass in men

A. Wierzbicki, I. Fogelman, A. Dolan, 2008, Clinical endocrinology.

A. Wierzbicki, R. Minhas, Rubin Minhas, 2009, International journal of clinical practice.

A. Wierzbicki, K. Patel, R. Minhas, 2008, BMJ : British Medical Journal.

Angiographic coronary artery disease and high‐sensitivity troponin‐T in a native Pakistani cohort presenting with chronic chest pain

S. Nishtar, P. Lumb, J. Gill, 2014, International journal of clinical practice.

Lipid-Lowering Agents

M. Ewang-Emukowhate, A. Wierzbicki, 2013, Journal of cardiovascular pharmacology and therapeutics.

Association of bone turnover markers and arterial stiffness in pre-dialysis chronic kidney disease (CKD).

M. Shearer, P. Chowienczyk, A. Wierzbicki, 2011, Bone.

Surrogate markers, atherosclerosis and cardiovascular disease prevention

A. Wierzbicki, A. Wierzbicki, 2008, International journal of clinical practice.

Rimonabant: endocannabinoid inhibition for the metabolic syndrome

A. Wierzbicki, A. Wierzbicki, 2006, International journal of clinical practice.

Ezetimibe‐induced hyperlipidaemia

A. Wierzbicki, E. Doherty, P. Lumb, 2005, International journal of clinical practice. Supplement.

Muddy waters: more stormy SEAS for ezetimibe

A. Wierzbicki, A. Wierzbicki, 2008, International journal of clinical practice.

Cyclosporine – a treatment and a rare complication: Raynaud's phenomenon

A. Wierzbicki, 2005, International journal of clinical practice.

Low-density lipoprotein apolipoprotein B100 turnover in hypopituitary patients with GH deficiency: a stable isotope study.

N. Jackson, A. Umpleby, P. Sönksen, 2006, European journal of endocrinology.

Effect of IGF-I therapy on VLDL apolipoprotein B100 metabolism in type 1 diabetes mellitus.

P. Carroll, A. Umpleby, P. Sönksen, 2002, American journal of physiology. Endocrinology and metabolism.

Effects of growth hormone (GH) replacement therapy on very low density lipoprotein apolipoprotein B100 kinetics in patients with adult GH deficiency: a stable isotope study.

A. Umpleby, P. Sönksen, E. Christ, 1999, The Journal of clinical endocrinology and metabolism.

Effects of growth hormone (GH) replacement therapy on low-density lipoprotein apolipoprotein B100 kinetics in adult patients with GH deficiency: a stable isotope study.

N. Jackson, A. Umpleby, P. Sönksen, 2004, The Journal of clinical endocrinology and metabolism.

Peroxisomes, Refsum's disease and the α- and ω-oxidation of phytanic acid

J. Trimmer, M. Bootman, M. Taussig, 2007 .

Interpreting clinical trials of diabetic dyslipidaemia: new insights

A. Wierzbicki, A. Wierzbicki, 2009, Diabetes, obesity & metabolism.

Abnormalities of very low density lipoprotein apolipoprotein B-100 metabolism contribute to the dyslipidaemia of adult growth hormone deficiency.

A. Umpleby, P. Sönksen, E. Christ, 1997, The Journal of clinical endocrinology and metabolism.

Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4α mutations in a large European collection

T. Hansen, O. Pedersen, S. Ellard, 2005, Diabetologia.

Preserved endothelial function in patients with severe hypertriglyceridemia and low functional lipoprotein lipase activity.

G. Watts, P. Chowienczyk, J. Ritter, 1997, Journal of the American College of Cardiology.

Lipid‐altering agents: the future

A. Wierzbicki, A. Wierzbicki, 2004, International journal of clinical practice.

Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease

W. Fraser, A. Wierzbicki, D. Goldsmith, 2010, Osteoporosis International.

Familial Hypercholesterolaemia in the Era of Genetic Testing

D. Hughes, A. Wierzbicki, A. Viljoen, 2016, Current Cardiology Reports.

The Poly‐pill: does it work and is chronic therapy acceptable?

A. Wierzbicki, R. Minhas, Rubin Minhas, 2010, International journal of clinical practice.

Metabolism of phytanic acid and 3-methyl-adipic acid excretion in patients with adult Refsum disease Published, JLR Papers in Press, April 16, 2003. DOI 10.1194/jlr.M300121-JLR200

M. D. Lloyd, A. Wierzbicki, M. Feher, 2003, Journal of Lipid Research.

SEARCHing for JUPITER: starry‐eyed optimism is not warranted

A. Wierzbicki, A. Wierzbicki, 2009, International journal of clinical practice.

Pro‐protein convertase subtilisin/kexin 9 concentrations correlate with coronary artery disease atheroma burden in a Pakistani cohort with chronic chest pain

S. Nishtar, A. Wierzbicki, M. Marber, 2015, International journal of clinical practice.

Statins and hypertension

A. Wierzbicki, A. Wierzbicki, 2006, Journal of Human Hypertension.

Structure-function analysis of phytanoyl-CoA 2-hydroxylase mutations causing Refsum's disease.

M. D. Lloyd, M. Mukherji, A. Wierzbicki, 2001, Human molecular genetics.